Patents Assigned to Henry M. Jackson Foundation for Advancement of Military Medicine
-
Patent number: 8883164Abstract: This invention relates generally to identifying peptide sequences involved in antibody binding to any protein for synthesis of vaccine treatments. This novel method allows for a more manageable vaccine peptide discovery and specific generation of unique immunogenic peptides from self-tumor associated proteins and/or foreign proteins from infectious organisms for specific and/or enhanced expression only in the presence of the antibody.Type: GrantFiled: December 23, 2011Date of Patent: November 11, 2014Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Sathibalan Ponniah, George E. Peoples, Catherine E. Storrer, Michael Flora
-
Patent number: 8871455Abstract: Methods and kits are provided for assessing radiation injury and exposure in a subject. The methods comprise measuring the levels of at least two (2) protein biomarkers from different biological pathways and correlating the levels with an assessment of radiation injury and exposure. Additional use of peripheral blood cell counts and serum enzyme biomarkers, evaluated in the early time frame after a suspected radiation exposure, and use of integrated multiple parameter triage tools to enhance radiation exposure discrimination and assessment are also provided. The information obtained from such methods can be used by a clinician to accurately assess the extent of radiation injury/exposure in the subject, and thus will provide a valuable tool for determining treatment protocols on a subject by subject basis.Type: GrantFiled: June 12, 2007Date of Patent: October 28, 2014Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: William Blakely, Natalia Ossetrova, Marcy Grace, Alexandra Miller, Jean Mulimbi Muderhwa, Glen Manglapus
-
Publication number: 20140315742Abstract: The present invention relates to methods and kits to assess an absorbed dose of ionizing radiation and/or the severity of tissue injury from radiation in a patient. The invention also relates to algorithms used to calculate an absorbed dose of radiation based on biomarker measurements of a plurality of biomarkers that are altered relative to a normal control in the event of radiation exposure.Type: ApplicationFiled: September 28, 2012Publication date: October 23, 2014Applicants: MESO SCALE TECHNOLOGIES, LLC, THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.Inventors: William F Blakely, Eli N. Glezer, John Kenten, Sudeep Kumar, Anu Mathew, Natalia I. Ossetrova, George Sigal
-
Patent number: 8865171Abstract: This invention relates to soluble forms of G glycoprotein from Hendra and Nipah virus. In particular, this invention relates to compositions comprising soluble forms of G glycoprotein from Hendra and Nipah virus and also to diagnostic and therapeutic methods using the soluble forms of G glycoprotein from Hendra and Nipah virus. Further, the invention relates to therapeutic antibodies including neutralizing antibodies, and vaccines for the prevention and treatment of infection by Hendra and Nipah viruses.Type: GrantFiled: July 7, 2005Date of Patent: October 21, 2014Assignee: The Henry M. Jackson Foundation For the Advancement of Military Medicine, Inc.Inventors: Christopher C. Broder, Katharine N. Bossart
-
Patent number: 8858639Abstract: Embodiments relate to systems and methods for a cranial implant assembly adapted for insertion during a craniectomy procedure. In aspects, the inventive cranial implant assembly can contain a peripheral attachment member for attachment to the edge of a skull opening, as well as an articulated spanning member that over-arches and holds a cover in place over the opening. The articulated spanning member contains a central implant fastened or connected to a swollen dura in the skull opening. As swelling of the dura subsides, tension is exerted on guidewires in both the spanning member and cover to draw those constructs into a rigid state. The tips of the spanning member can gradually approach the peripheral attachment member, and register into place using a locking mechanism, such as a pair of opposing magnets. As a result, only one surgical operation or procedure Is required to both perform a craniectomy and implant a supporting assembly for eventual skull regeneration.Type: GrantFiled: July 29, 2011Date of Patent: October 14, 2014Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventor: Teodoro Aclan Tigno, Jr.
-
Patent number: 8858938Abstract: The present invention relates to monoclonal antibodies that bind or neutralize Hendra or Nipah virus. The invention provides such antibodies, fragments of such antibodies retaining Hendra or Nipah virus-binding ability, fully human antibodies retaining Hendra or Nipah virus-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.Type: GrantFiled: September 13, 2013Date of Patent: October 14, 2014Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, The Henry M. Jackson Foundation of the Advancement of Military Medicine, Inc.Inventors: Dimiter S. Dimitrov, Zhongyu Zhu, Christopher C. Broder
-
Patent number: 8846330Abstract: The present invention encompasses methods for diagnosis of calcium channel related diseases (e.g., RyR1-related diseases) comprising contacting lymphocytes isolated from a subject with a calcium channel agonist (e.g., an RyR1 agonist), measuring the adenosine and inosine produced by the lymphocytes; and comparing the measured levels in the sample to the adenosine and inosine levels in a normal control, whereby an increase in the adenosine and inosine levels relative to the control is indicative of a calcium channel related disease (e.g., RyR1-related disease). The invention also encompasses kits for diagnosis of calcium channel-related diseases.Type: GrantFiled: September 8, 2009Date of Patent: September 30, 2014Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Saiid Bina, Rolf Bunger
-
Patent number: 8846058Abstract: A chimeric Shiga toxoid according to the invention contains an enzymatically-inactivated StxA subunit and a native StxB subunit. This hybrid Shiga toxoid induces the production of broadly cross-reactive species of antibodies against Shiga toxin following immunization. The StxA subunit is modified so that it is enzymatically inactive. The invention thus encompasses the Shiga toxoid or fragments thereof and the nucleic acid sequence of the Shiga toxoid or fragments thereof. The invention further encompasses the production of a Shiga toxoid, the production of antibodies using the Shiga toxoid and methods of productions, and an immunogenic composition containing the Shiga toxoid.Type: GrantFiled: February 16, 2007Date of Patent: September 30, 2014Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Michael J. Smith, Alison D. O'Brien, Louise D. Teel, Angela R. Melton-Celsa
-
Patent number: 8815256Abstract: The present invention is directed to variants of antigens comprising folate binding protein epitopes as a composition associated with providing immunity against a tumor in an individual. The variant is effective in inducing cytotoxic T-lymphocytes but preferably not to the extent that they become sensitive to silencing by elimination, such as by apoptosis, or by anergy, as in unresponsiveness.Type: GrantFiled: July 24, 2012Date of Patent: August 26, 2014Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Constantin G. Ioannides, George E. Peoples, Kathleen G. Peoples
-
Publication number: 20140227339Abstract: A graft containing a scaffold that includes a matrix in which are positioned mesenchymal progenitor cells (MPCs) has the capacity to substantially improve wound healing, including wounds resulting from injury to nerve, bone and vascular tissue. MPCs can be harvested from debrided muscle tissue following orthopaedic trauma. The traumatized muscle-derived progenitor cells are a readily available autologous cell source that can be utilized to effect or improve wound healing in a variety of therapeutic settings and vehicles.Type: ApplicationFiled: February 12, 2014Publication date: August 14, 2014Applicants: THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC., THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF, THE UNITED STATES GOVERNMENT, AS REPRESENTED BY THE SECRETARY OF THE ARMY, U.S.A.Inventors: Wesley M. Jackson, Leon J. Nesti, Rocky S. Tuan
-
Patent number: 8802618Abstract: The invention provides a method for the creation of peptide antigens comprising epitopes with at least a first modification comprising a shortened or lengthened amino acid side chain. By extension or shortening of the side chain with CH3/CH2 groups, for example, made by computer assisted modeling of the tumor antigen (peptide) bound in the MHC-I-groove, immunogenicity can be improved with minimal modification of adjacent tertiary structure, thereby avoiding cross-reactivity. Provided by the invention are methods of creating such antigens, as well as methods for therapeutic or prophylactic treatment of various conditions comprising administration of the antigens.Type: GrantFiled: March 6, 2003Date of Patent: August 12, 2014Assignees: Board of Regents, The University of Texas System, Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Constantin G. Ioannides, Martin L. Campbell, Catherine A. O'Brian, George E. Peoples
-
Publication number: 20140220072Abstract: Recombinant vectors comprising the cell entry region of the Shigella ox EIEC invasion plasmid are provided, as well as, Shigella or EIEC strains comprising the recombinant vectors. The vectors provide an improved platform for developing attenuated vaccine strains of Shigella or EiEC and for delivering other foreign proteins of interest. The recombinant vectors and bacterial strains comprising the same may be used in methods of inducing an immune response.Type: ApplicationFiled: September 13, 2012Publication date: August 7, 2014Applicant: THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INCInventor: Anthony T. Maurelli
-
Publication number: 20140220107Abstract: The instant application provides methods and related compositions pertaining to novel HIV envelope proteins. In some embodiments, the invention relates to methods and compositions for the preparation, production, and administration of isolated novel HIV envelope nucleic acid and protein sequences suitable, for example, as vaccines against HIV.Type: ApplicationFiled: April 25, 2012Publication date: August 7, 2014Applicants: ADVANCED BIOSCIENCE LABORATORIES, INC., HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, THE GOVERNMENT OF THE USA, AS REPRESENTED BY THE SECRETARYInventors: Vaniambadi Kalyanaraman, Stephen Whitney, Thomas C. Vancott, Victoria Polonis, Carl Alving, Gary R. Matyas, Mangala Rao, Mary Marovich, Francine McCutchan, Sodsai Tovanabutra, Eric Sanders-Buell
-
Patent number: 8796220Abstract: The invention features methods to induce and maintain a protective cytotoxic T-lymphocyte response to a peptide of the HER2/neu oncogene, E75, with the effect of inducing and maintaining protective or therapeutic immunity against breast cancer in a patient in clinical remission. The methods comprise administering to the patient an effective amount of a vaccine composition comprising a pharmaceutically acceptable carrier, an adjuvant such as recombinant human GM-CSF, and the E75 peptide at an optimized dose and schedule. The methods further comprise administering an annual or semi-annual booster vaccine dose due to declining E75-specific T cell immunity. The invention also features vaccine compositions for use in the methods.Type: GrantFiled: June 27, 2012Date of Patent: August 5, 2014Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: George Peoples, Sathibalan Ponniah
-
Publication number: 20140193833Abstract: Provided are methods of using polycarbonate filters to isolate and detect cancer cells in a biological fluid, particularly biological fluids, such as urine, that contain very low concentrations of cancer cells. The characterization of the isolated cells for the presence or absence of cancer specific proteins is useful for cancer diagnosis and prognosis.Type: ApplicationFiled: August 8, 2012Publication date: July 10, 2014Applicant: THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.Inventors: Shiv K. Srivastava, Petrovics Gyorgy, Shyh-Han Tan, Kristen Nickens
-
Publication number: 20140182594Abstract: A manually operable pump for the effective removal of fluids to include blood, blood clots, fluid, and air from a body cavity of a subject is provided. The manually operable pump is adapted to be connect to a range of fluid conduits and is equipped with one-way valves that effectively permit flow of fluid through the pump in only one direction. The sensitivity of the one-way valves is such that when properly positioned, fluid can flow through the valves and out of the pump without manual compression of the pump and with the aid of gravity power alone.Type: ApplicationFiled: January 23, 2014Publication date: July 3, 2014Applicant: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Hasan B. Alam, Peter Rhee, Emily Rhee
-
Patent number: 8765916Abstract: Monoclonal antibodies, or antigen-binding fragments thereof, that bind to ERG, and more specifically, to an epitope formed by amino acids 42-66 of ERG3 are disclosed. The monoclonal antibodies can be non-human antibodies (e.g., rabbit or mouse) or humanized monoclonal antibodies having the CDR regions derived from those non-human antibodies. In other embodiments, the monoclonal antibodies are chimeric, having the light and heavy chain variable regions of a non-human ERG antibody. Methods of using the antibodies to detect ERG, or fusion proteins comprising all or part of an ERG polypeptide, such as an ERG polypeptide encoded by a TMPRSS2/ERG, SLC45A3/ERG, or NDRG1/ERG fusion transcript, are also provided, including methods of detecting ERG or ERG fusion events in a clinical setting.Type: GrantFiled: April 28, 2010Date of Patent: July 1, 2014Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Shiv Srivastava, Shyh-Han Tan, Albert Dobi
-
Patent number: 8765146Abstract: The invention provides adenoviral vectors comprising an adenoviral genome comprising heterologous antigen-encoding nucleic acid sequences, such as Plasmodium nucleic acid sequences, operably linked to promoters. The invention further provides a method of inducing an immune response against malaria in a mammal comprising administering the adenoviral vectors to the mammal.Type: GrantFiled: August 31, 2006Date of Patent: July 1, 2014Assignees: GenVec, Inc., The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The United States of America, as represented by the Secretary of the NavyInventors: Joseph T. Bruder, Imre Kovesdi, C. Richter King, Duncan L. McVey, Damodar R. Ettyreddy, Denise Louise Doolan, Daniel John Carucci
-
Publication number: 20140135481Abstract: The present invention describes the preparation and use of biologically and immunologically active humanized monoclonal antibodies to Shiga toxin, a toxin associated with HC and the potentially life-threatening sequela HUS transmitted by strains of pathogenic bacteria. The present invention describes how these humanized antibodies may be used in the treatment or prevention of Shiga toxin induced diseases. One aspect of the invention is the humanized monoclonal antibody which binds Shiga toxin where the constant regions are IgG1-kappa and the variable regions are murine in origin. Yet another aspect of the invention is expression vectors and host cells transformed with such vectors which express the humanized monoclonal antibodies of the present invention.Type: ApplicationFiled: September 25, 2013Publication date: May 15, 2014Applicant: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Jeffrey R. Stinson, Hing Wong, Alison D. O'Brien, Clare K. Schmitt, Angela Melton-Celsa
-
Patent number: 8711342Abstract: A joulemeter is capable of non-destructively measuring multiple characteristics of a laser beam. The joulemeter comprises a series of parallel probe beams, which are directed though a transparent media adjacent to an absorbing media that the tested beams pass through. Arrays of optical sensors or a chirp sensor are used to intercept and measure deflections the probe beams. A control unit renders measurements on selected properties of the laser.Type: GrantFiled: August 11, 2008Date of Patent: April 29, 2014Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: William Rowe Elliott, Randolph D. Glickman, Norman Barsalou, Saher M. Maswadi